Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 17.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | n Form 8-K is incorporated by reference into this Item 5.02. In connection with the consummation of the Merger, each of |
| 24.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 22.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 28.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compen |
| 14.05.2024 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | 3(a) of the Exchange Act. ☐ Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report |
| 21.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 11.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 13.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Unternehmen & Branche
| Name | Evoke Pharma Inc |
|---|---|
| Ticker | EVOK |
| CIK | 0001403708 |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 18,9 Mio. USD |
| Beta | -0,14 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-09-30 | 10-Q | 4,283,979 | -1,156,208 | -0.45 | 15,649,433 | 3,362,236 |
| 2025-06-30 | 10-Q | 3,752,142 | -1,570,976 | -0.62 | 16,060,328 | 4,374,492 |
| 2025-03-31 | 10-Q | 3,080,158 | -1,306,178 | -0.51 | 16,375,945 | 5,841,215 |
| 2024-12-31 | 10-K | 10,249,415 | -5,352,194 | -2.81 | 17,519,007 | 7,038,010 |
| 2024-09-30 | 10-Q | 2,654,186 | -1,312,390 | -0.94 | 14,153,571 | 4,387,136 |
| 2024-06-30 | 10-Q | 2,551,366 | -1,267,218 | -0.93 | 12,136,215 | 2,664,958 |
| 2024-03-31 | 10-Q | 1,735,490 | -1,579,820 | -2.09 | 12,453,962 | 3,497,169 |
| 2023-12-31 | 10-K | 5,180,630 | -7,792,295 | -27.97 | 7,068,546 | -2,579,537 |
| 2023-09-30 | 10-Q | 1,562,860 | -1,693,907 | -6.08 | 7,852,974 | -873,775 |
| 2023-06-30 | 10-Q | 1,131,368 | -1,579,820 | -6.71 | 8,979,697 | 538,374 |
| 2023-03-31 | 10-Q | 810,408 | -2,243,070 | -0.67 | 10,039,307 | 2,126,151 |
| 2022-12-31 | 10-K | 2,508,645 | -5,352,194 | -2.62 | 11,851,488 | 4,084,649 |
| 2022-09-30 | 10-Q | 832,100 | -2,013,864 | -0.60 | 13,410,520 | 5,532,898 |
| 2022-06-30 | 10-Q | 461,795 | -2,233,380 | -0.71 | 14,404,396 | 7,191,010 |
| 2022-03-31 | 10-Q | 418,380 | -2,173,665 | -0.80 | 9,026,270 | 1,934,011 |
| 2021-12-31 | 10-K | 1,618,076 | -8,537,952 | -3.18 | 10,573,162 | 3,555,094 |
| 2021-09-30 | 10-Q | 930,449 | -1,969,452 | -0.73 | 11,649,959 | 4,773,256 |
| 2021-06-30 | 10-Q | 236,635 | -2,290,643 | -0.85 | 17,557,281 | 5,965,606 |
| 2021-03-31 | 10-Q | 90,421 | -2,605,495 | 19,295,950 | 7,811,384 | |
| 2020-12-31 | 10-K | 23,020 | -13,154,671 | 9,434,048 | -3,214,623 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-06 | Klein Roger M. | 10% Owner | Open Market Sale | -4,000 | 10.65 | -42,600.00 | -88,9% | |
| 2025-11-06 | Klein Roger M. | 10% Owner | Open Market Sale | -5,000 | 10.66 | -53,285.00 | -111,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.